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AbstrAct:
Recent studies have demonstrated the significance of the leukemia oncogene Evi1 
as the regulator of hematopoietic stem cells and marker of poor clinical outcomes in 
myeloid malignancies. Evi1-mediated leukemogenic activities include a wide array of 
functions such as the induction of epigenetic modifications, transcriptional control, 
and regulation of signaling pathways. We have recently succeeded in comprehensively 
elucidating the oncogenic function of Evi1 in a model of the polycomb-Evi1-PTEN/
AKT/mTOR axis. These results may provide us with novel therapeutic approaches 
to conquer the poor prognosis associated with Evi1-activated leukemia or other 
solid tumors with high Evi1 expression. Here, we review the current understanding 
of the role of Evi1 in controlling the development of leukemia and highlight 
potential modalities for targeting factors involved in Evi1-regulated signaling.
INtrODUctION
Ecotropic viral integration site 1 (Evi1) is a nuclear 
zinc finger protein that is essential for the proliferation 
and  maintenance  of  hematopoietic  stem  cells  (HSC) 
[1]. Clinically, activated Evi1 expression is observed in 
approximately 10% of patients with acute myeloid leukemia 
(AML) and is an independent factor associated with poor 
prognosis in AML [2-4]. Evi1 is located on chromosome 
3q26,  and  the  up-regulation  of  Evi1  expression  was 
originally found to be a consequence of inv(3)(q21q26.2) 
or t(3;3)(q21;q26.2) [5,6]. In addition, we have recently 
shown  that  Evi1  is  transcriptionally  up-regulated  by 
oncogenic MLL fusion proteins [7]; around half of the 
patients with AML having 11q23 rearrangements display 
high  Evi1  expression  [2].  Chromosomal  abnormalities 
involving  chromosome  7  are  another  candidate  cause 
of Evi1 activation [2,8]. Molecularly, Evi1 has a variety 
of functions as an oncoprotein. Firstly, it regulates some 
signaling  pathways.  The  most  characterized  function 
is  the  negative  control  exerted  by  Evi1  on  TGF-β 
signaling through the repression of Smad3 function by 
physical interaction and recruitment of the corepressor 
CtBP  [9,10];  this  may  contribute  to  the  leukemogenic 
activity of Evi1 by promoting cellular proliferation and 
affecting cellular differentiation. Moreover, Evi1 exerts 
anti-apoptotic effects by suppressing the JNK1-mediated 
phosphorylation of c-Jun [11] or inhibiting interferon-α 
signaling through the regulation of the PML gene [12]. 
Secondly, Evi1 has been shown to act as a transcriptional 
factor and regulate the expression of several target genes 
by  directly  binding  DNA  through  its  proximal  zinc 
finger  domain  and  recognizing  a  consensus  sequence 
consisting  of  GA(C/T)AAGA(T/C)AAGATAA-like  or 
GACAAGATA-like motifs [13,14]. We and other groups 
have  reported  that  Evi1  regulates  GATA2  [14],  PBX1 
[15], and PML [12] transcription. Thirdly, recent studies 
have  indicated  that  Evi1  actively  induced  epigenetic 
changes by interacting with various molecules. In this 
perspective, we will discuss the novel oncogenic functions 
of Evi1, particularly focusing on the relationship between 
leukemogenesis and epigenetics or signaling pathways. 
EpIgENEtIcs IN lEUkEmOgENEsIs
Although  cancer  development  has  been 
considered  a  consequence  of  genetic  changes,  it  has 
become  increasingly  evident  that  it  also  involves 
epigenetic changes that are mechanisms affecting gene 
expression  profiles  without  alterations  in  the  DNA 
sequence. Such mechanisms include DNA methylation, 
histone  modification,  and  microRNA  involvement.  In Oncotarget 2011; 2:  575 - 586 576 www.impactjournals.com/oncotarget
hematological malignancies, recent findings of frequent 
mutations in epigenetic regulators such as EZH2 [16-18], 
DNMT3A [19-21], TET2 [22,23], ASXL1 [24], and UTX 
[25]  support  the  idea  that  dysregulation  of  epigenetics 
plays  a  role  in  leukemogenesis  [26,27].  For  example, 
somatic mutations in EZH2 are frequently identified in 
myeloid  malignancies,  particularly  in  myelodysplastic 
syndrome  and  myeloproliferative  neoplasms  [16-18]. 
EZH2 is a core component of the polycomb repressive 
complex  2  (PRC2)  and  catalyzes  histone  3  lysine  27 
(H3K27) trimethylation in association with SUZ12 and 
EED. Another complex called PRC1 possesses histone 2A 
lysine 119 E3 ubiquitin ligase activities, and these histone 
modifications are essential for the silencing of polycomb 
target  genes,  which  in  turn  regulate  a  broad  array  of 
biological processes such as the cell cycle, apoptosis, stem 
cell regulation, senescence, and cancer development [28-
32]. Most of the missense mutations of EZH2 occurred 
in the CXC-SET domain and domain II, both of which 
are  essential  for  the  histone  methyltransferase  activity. 
Therefore,  truncated  or  missense  mutations  in  EZH2 
observed  in  myeloid  malignancies  are  supposed  to  be 
inactivating mutations [16], and EZH2 may be a tumor 
suppressor  in  this  context.  On  the  other  hand,  intact 
polycomb  group  (PcG)  proteins  function  as  oncogenic 
silencers in other contexts, as shown below. 
EvI1 lINks thE EpIgENEtIc 
mAchINEry tO thE rEgUlAtION 
Of Its tArgEt gENE/sIgNAlINg 
pAthwAy 
We  have  recently  found  that  Evi1  physically 
interacts with PcG proteins (EZH2, SUZ12, EED, BMI1, 
RING1, RING2, and HPH2) [33]. However, it appeared 
that Evi1 expression did not affect the global methylation 
status of H3K27 (data not shown). This finding prompted 
us  to  investigate  specific  target  genes  of  Evi1  whose 
expressions were repressed in concert with PcG proteins. 
Our microarray data using primary bone marrow (BM) 
progenitors with forced expression of Evi1 and some sets of 
published gene expression data from AML samples [4,34] 
were combined and bioinformatically analyzed, leading to 
the identification of the tumor suppressor PTEN as a novel 
repressive target of Evi1. Chromatin immunoprecipitation 
(ChIP) assays using Evi1-transduced BM cells indicated 
that  Evi1  induced  H3K27  trimethylation  marks  on  the 
PTEN  genomic  locus  by  recruiting  PcG  proteins.  As 
PTEN  is  a  well-established  tumor  suppressor  and  acts 
as a negative regulator of the PI3K/AKT pathway, and 
we found that Evi1 activated the AKT/mTOR signaling 
pathway through transcriptional repression of PTEN. The 
activation of this signaling is essential for Evi1-mediated 
leukemogenesis, as discussed later. Interestingly, RNAi-
mediated knockdown of EZH2 restored PTEN expression 
and down-regulated the AKT/mTOR activities in Evi1-
transduced BM cells, suggesting that Evi1 functions as a 
platform to recruit PcG proteins to the PTEN locus (Figure 
1). In accordance with the aforementioned concept, the 
effects of EZH2 knockdown on PTEN expression were 
not  observed  in  BM  cells  with  low  Evi1  expression. 
In other words, EZH2 can act as an oncoprotein in the 
presence of high Evi1 expression. Another example of 
the oncogenic function of EZH2 has been investigated in 
acute promyelocytic leukemia (APL). APL is induced by a 
differentiation block and an overgrowth of promyelocytes 
attributed to chromosomal translocation, leading to the 
production of fusion proteins such as PML/RARα and 
PLZF/RARα. These chimeric proteins have been shown 
to recruit PcG complexes to the target gene promoters 
through the RARα moiety and block cell differentiation 
[35,36].  Therefore,  such  oncogenic  functions  of  PcG 
proteins can be therapeutic targets (Figure 1). In addition, 
we  confirmed  that  Evi1-transduced  BM  cells  show 
specifically  increased  sensitivity  to  a  PRC2  inhibitor 
[3-Deazaneplanocin A (DZNep)] (data not shown). 
Increasing evidence indicating the involvement of 
Evi1  in  the  epigenetic  regulation  of  gene  transcription 
has  been  recently  accumulated.  Lugthart  et  al.  have 
shown that AML samples with activated Evi1 presented 
with a deregulated hypermethylation signature, possibly 
through physical interactions between Evi1 and the DNA 
methyltransferases DNMT3A and DNMT3B [37]. Their 
genome-wide DNA methylation profiling revealed about 
300 promoters (out of the 14000 tested) with abundant 
cytosine methylation, and ChIP assays for the purpose 
of validation identified some Evi1 target genes such as 
FAM83b,  CRHBP,  VPREB3,  and  IL11RA.  Given  that 
EZH2 has been reported to interact with DNMT3A and 
DNMT3B  [38],  the  two  reports  on  Evi1  and  histone/
DNA  methyltransferases  may  support  each  other  in 
demonstrating that Evi1 repressed target gene transcription 
through, at least in part, PcG-DNMT complex-mediated 
epigenetic modifications. 
Besides PcG proteins and DNMTs, we and other groups 
have demonstrated that Evi1 recruits epigenetic regulators 
for  controlling  transcription.  For  example,  SUV39H1 
and  G9a  are  H3K9  methyltransferases  associated  with 
gene silencing [39,40], and they also interact with Evi1 
[41-43]. Reporter assays have indicated that SUV39H1 
synergistically suppressed the transcriptional activity of 
Evi1, and knockdown of SUV39H1 or G9a specifically 
reduced the colony-forming activity of Evi1-transduced 
BM  cells,  suggesting  that  H3K9  methyltransferases 
are  actively  involved  in  Evi1-associated  oncogenic 
functions, possibly through the epigenetic repression of 
putative Evi1 target genes. In addition, Evi1 physically 
associated with the methyl-CpG binding protein 3b [44] 
and histone deacetylases 1 [45], both of which are the 
core  components  of  the  NuRD  complex  that  harbors Oncotarget 2011; 2:  575 - 586 577 www.impactjournals.com/oncotarget
histone  deacetylase  activity  and  induces  transcriptional 
repression [46,47]. Evi1 associates with Brahma-related 
gene 1 (BRG1; also known as SMARCA4 and SNF2β), a 
member of the SWI/SNF chromatin-remodeling complex 
[48].  In  reporter  assays,  the  authors  have  shown  that 
Evi1  activated  the  E2F1  promoter  in  association  with 
BRG1, which suggested that Evi1 enhanced cell cycling 
and  cellular  proliferation  through  the  up-regulation  of 
E2F1 by interacting with the SWI/SNF complex. Taken 
together, these data suggest that Evi1 has the potential 
to induce transcriptional repression by recruiting higher 
order chromatin remodeling complexes. 
Along  with  chromatin  remodeling  factors, 
microRNAs  play  a  part  in  epigenetic  regulation,  and 
recent findings have clarified that Evi1 regulates some 
microRNAs. Dickstein et al. have demonstrated that Evi1 
silenced miRNA-124 expression through the methylation 
of CpGs located around miRNA-124 [49]. In addition, 
they  have  shown  that  Evi1  induction  in  Lin− murine 
BM cells increased the expression of BMI1 and cyclin 
D3, whereas forced expression of miRNA-124 in Evi1-
transduced  murine  BM  cells  restored  their  expression. 
Furthermore, Gomez-Benito et al. have recently shown 
that Evi1 directly bound to the miR-1-2 promoter region 
and up-regulated its expression, which may have a role 
in the Evi1-mediated proliferation activity, as shown by 
transient transfection assays using AML cell lines [50]. 
Likewise,  Evi1  has  been  suggested  to  increase  K-ras 
oncoprotein  expression  through  the  direct  repression 
of  miR-143  in  colon  cancer  [51].  The  authors  argued 
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figure 1:Evi1 induces epigenetic regulation on pI3k/ptEN/Akt/mtOr signaling. In cells with high Evi1 expression, Evi1 
recruits polycomb repressive complexes (PRC1 and PRC2) to the PTEN locus and epigenetically represses PTEN transcription, which in 
turn stimulates AKTand mTOR. These regulatory mechanisms are activated only in cells with high Evi1 expression.Oncotarget 2011; 2:  575 - 586 578 www.impactjournals.com/oncotarget
that the Evi1/miR-143/K-ras axis contributed to colonic 
carcinogenesis  by  enhancing  proliferation  capacity  and 
motility. 
These data strongly suggest that Evi1 regulates target 
gene transcription by mobilizing epigenetic mechanisms. 
pI3k/Akt/mtOr sIgNAlINg IN EvI1-
mEDIAtED lEUkEmOgENEsIs 
Next, we focused on the PI3K/PTEN/AKT/mTOR 
signaling  pathway  in  leukemia  (overviewed  in  Figure 
2;  see  other  review  articles  such  as  [52-54]  for  more 
detailed information). As presented above, Evi1 recruited 
polycomb  complexes  to  the  PTEN genomic locus and 
activated the AKT/mTOR signaling pathway through the 
transcriptional repression of PTEN [33]. On the basis of 
these observations, we established a murine AML model 
with high Evi1 expression by BM transplantation and aimed 
to test the efficacy of the mTOR inhibitor rapamycin on 
the leukemia model in vivo. Administration of rapamycin 
significantly  prolonged  the  survival  of  diseased  mice, 
suggesting that the AKT/mTOR pathway played a role in 
the proliferation and survival of the Evi1-expressing AML 
cells. Moreover, we investigated the effects of rapamycin 
on  other  leukemia  models  established  by  transduction 
of  the  AML1  mutant  (AML1_S291fsX300)  [55]  and 
coexpression of TEL/PDGFβR and AML1/ETO [56] and 
found no changes in their survival; this demonstrated the 
specific  sensitivity  of  Evi1-activated  leukemia  cells  to 
rapamycin (Figure 1). 
Extensive  studies  regarding  PI3K/AKT/mTOR 
signaling  and  leukemia  have  demonstrated  that  PI3K/
AKT signaling is frequently activated in AML [57,58]. In 
particular, AKT phosphorylation on Ser473 was detected 
in over half of the patients with AML [57]. As demonstrated 
by Tamburini et al. and Xu et al., downstream mTORC1 is 
constitutively activated in primary AML samples [58,59]. 
However,  the  mechanisms  of  PI3K/AKT/mTORC1 
activation remain largely unclear. PTEN and SHIP are 
negative regulators of PIP3 and downstream AKT/mTOR 
signaling. Xu et al. have shown that PTEN expression was 
down-regulated in a few patients with AML, but PTEN 
expression  levels  were  not  inversely  correlated  with 
AKT phosphorylation levels for an unknown reason [58]. 
Gene mutation analysis of PTEN and SHIP has revealed 
that  mutations  in  these  genes  are  uncommon  [60,61] 
although a SHIP-V684E mutation was found in one out 
of 30 patients with AML. This mutation reduced catalytic 
function and enhanced AKT phosphorylation, which may 
contribute  to  leukemogenesis  [61].  On  the  other  hand, 
PTEN  phosphorylation  levels  have  been  analyzed  in 
AML.  Phosphorylated  PTEN  was  positively  correlated 
with  AKT  phosphorylation  (Figure  2)  and  was  found 
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in  74%  of  patients  with AML  [62].  The  authors  have 
demonstrated that phosphorylated PTEN is a predictor of 
clinical outcome in patients with AML. 
With  regard  to  PI3K/PTEN/AKT  signaling  as  a 
prognostic factor, some controversial results have been 
reported by several groups. Min et al. have shown that 
phosphorylation of AKT on Ser473 and Thr308 confers 
poor prognosis in AML [63]. Kornblau et al. have shown 
similar results using a Ser473-specific antibody ([64] and 
personal communication with S. Kornblau). Meanwhile, 
Tamburini et al. have evaluated as many as 188 patients 
and demonstrated that constitutive activation of PI3K was 
associated with better prognosis [57]. Furthermore, Gallay 
et al. have shown that AKT phosphorylation on Thr308, but 
not on Ser473, predicted an adverse outcome in AML [65]. 
These complicated data may be partly explained by the 
heterogeneity of leukemic cells used in evaluating PI3K/
AKT  phosphorylation  [57,63,64].  Intracellular  FACS 
staining and antibodies of high quality have enabled us to 
measure the phosphorylation status of a small amount of 
cells such as an immature population with CD34+, CD38−, 
and  CD123+  phenotypes,  wherein  leukemia  stem  cells 
(LSCs) are supposed to be enriched [65,66]. Given that 
the PTEN/AKT/mTOR pathway plays an essential role 
in leukemia-initiating cells [67,68], the evaluation of this 
pathway in a purified leukemia population may provide 
some important insights. In addition, the aforementioned 
discrepancy may be attributed to the existence of cross-
activation with other pathways or feedback systems in 
leukemic cells, as shown by Kornblau et al. that ERK and 
PKCα were more likely to be activated in leukemic cells 
with  AKT  phosphorylation  than  statistically  expected 
([64]; Excellent reviews on the cross-talk among the RAF/
MEK/ERK,  PI3K/PTEN/AKT/mTOR,  and  JAK/STAT 
pathways are available: [69,70]). 
Our experimental model using murine primary BM 
has  allowed  the  demonstration  of  one  of  the  possible 
mechanisms  of  AKT/mTOR  activation  through  PTEN 
repression in AML. We confirmed an inverse correlation 
between  Evi1  and  PTEN  mRNA  expression  levels  in 
human  AML  and  chronic  myeloid  leukemia  (CML) 
samples  but  have  not  checked  the  status  of  AKT/
mTOR  signaling.  Thus,  these  data  suggest  the  need 
for  investigating  whether  Evi1-mediated  AKT/mTOR 
activation in mice is recapitulated in human leukemia. 
Large  scale  studies  applying  a  proteomic  approach  to 
human  leukemic  samples  will  provide  comprehensive 
insight into the regulation of signaling pathways. 
hsc, lsc, AND thE EvI1-ptEN AxIs
Pten depletion in murine adult hematopoietic cells 
has  caused  short-term  HSC  expansion  and  long-term 
depletion of the HSC pool [67,68]. When Pten-deficient 
HSCs were transplanted into recipient mice, they could not 
reconstitute multilineage hematopoiesis. Moreover, Pten 
depletion has been shown to induce myeloproliferative 
neoplasms and their progression to acute leukemia, which 
may  partly  be  a  reflection  of  genomic  instability  [71]. 
Yilmaz et al. have demonstrated that rapamycin restored 
normal HSC function and effectively depleted leukemia-
initiating cells simultaneously [67], suggesting that mTOR 
plays a significant role downstream of the PI3K/PTEN/
AKT axis and can be an ideal therapeutic target. 
Given that Evi1 is essential for HSC proliferation 
and myeloid leukemia cells [1], the Evi1-PTEN axis may 
potentially contribute to HSC and LSC regulation. Peng et 
al. have shown that BCR/ABL repressed PTEN in CML, 
and  this  repression  was  important  for  leukemogenesis 
[72,73]. The authors isolated Lin−, ckit+, and Sca1+ cells 
from BCR/ABL-induced and both BCR/ABL and PTEN-
induced CML  mice and  transplanted the same  number 
of each leukemic cell into the secondary recipient mice. 
The survival of the mice receiving LSCs transduced with 
both BCR/ABL and PTEN was significantly longer than 
that of the control mice, indicating that PTEN negatively 
regulated  LSC  functions.  These  results  are  consistent 
with  our  expression  profiling  of  human  CML  samples 
showing an inverse correlation between Evi1 and PTEN 
levels and a tendency of Evi1 to be activated as the disease 
progresses from the chronic phase to blastic crisis [33]. 
Therefore, the Evi1-PTEN axis may play a role in LSC 
functions and the progression of leukemia. 
rApAmycIN mAy Act As A mUltI-
fUNctION AgENt IN A rEcIpIENt Of 
AllOgENEIc hsct
Rapamycin binds to the FK506 binding protein 1A 
to  form  an  immunosuppressive  complex  that  inhibits 
mTOR and exerts antiviral, antifungal, antineoplastic, and 
immunosuppressive properties [74,75]. On the basis of the 
antineoplastic activities in preclinical studies, the efficacy 
of rapamycin (Sirolimus; Wyeth, Collegeville, PA, USA) 
and its analogs (rapalogs) has been investigated in clinical 
trials for the treatment of leukemia or lymphoma, and 
promising  results  have  begun  to  be  reported  [76-86]. 
For instance, Recher et al. have shown that rapamycin 
achieved  significant  clinical  response  against  four  out 
of nine patients with either refractory/relapsed de novo 
AML or refractory secondary AML [87]. In addition to 
its  antineoplastic  efficacy,  rapamycin  suppresses  T-cell 
proliferation/activation and has been used in the treatment 
of  graft  versus  host  disease  (GVHD)  after  allogeneic 
hematopoietic  stem  cell  transplantation  (HSCT) 
[74,77,78,88-94]. In allogeneic HSCT for patients with 
lymphoma, a retrospective study comparing the outcome 
of  GVHD  prophylaxis  between  rapamycin-containing 
regimens and a combination of calcineurin inhibitor and 
methotrexate  without  rapamycin  was  conducted  [95]. 
Intriguingly, the use of rapamycin significantly decreased 
disease progression without any differences in nonrelapse Oncotarget 2011; 2:  575 - 586 580 www.impactjournals.com/oncotarget
mortality  in  patients  who  underwent  reduced-intensity 
conditioning  regimens.  This  suggested  that  rapamycin 
can serve the dual purpose of an immunosuppressant and 
an antineoplastic agent. In addition, several reports have 
suggested the possibility that rapamycin exerts inhibitory 
effect  on  GVHD  without  interfering  with  graft  versus 
leukemia (GVL) effect [96,97] (Figure 3). Moreover, Marty 
et al. reported that rapamycin-based GVHD prophylaxis 
reduced  cytomegalovirus  reactivation  [98],  which  is 
still one of the challenging problems in HSCT because 
of the toxicity of cytomegalovirus itself or ganciclovir 
treatment-related toxicities such as myelosuppression and 
consequent risk of graft failure. On the other hand, the use 
of rapamycin or its analog, everolimus, may increase the 
risk of sinusoidal obstruction syndrome (veno-occlusive 
disease) under certain situations and lead to renal 
dysfunction, encephalopathy, and multiple organ failure, 
which is associated with high mortality [99,100]. Thus, 
the outcomes of large prospective trials that multilaterally 
evaluate the efficacy and toxicity of these agents in the 
treatment of leukemia and allogeneic HSCT are awaited. 
cONclUsIONs AND fUtUrE 
DIrEctIONs
Recent extensive studies have greatly increased our 
understanding of the roles of epigenetic regulation and 
signaling pathways in normal and malignant cells at the 
molecular  level.  These  studies  have  demonstrated  that 
the  leukemia  proto-oncoprotein  Evi1  formed  a  bridge 
between the epigenetic machinery and signaling pathways 
and  proposed  therapeutic  targets  for  the  eradication  of 
Evi1-related myeloid malignancies. 
Recent  studies  have  demonstrated  that  Evi1  is 
a  strong  inducer  of  epigenetic  regulation  of  multiple 
genomic  regions  in  hematopoietic  cells.  Clinical  trials 
targeting patients with hematological malignancies have 
shown  some  efficacies  and  limitations  of  epigenetic 
agents such as histone deacetylase inhibitors and DNA 
methyltransferase  inhibitors  (reviewed  in  [101-105]). 
However,  whether  these  drugs  have  the  capacity  to 
specifically  counteract  Evi1-mediated  leukemogenic 
activity  is  unclear.  Considering  the  marked  clinical 
heterogeneity  of  hematological  malignancies, 
accumulation  of  the  results  of  epigenetic  therapies  on 
the basis of molecularly defined clusters will be essential 
for  the  appropriate  use  of  epigenetic  drugs.  Efficient 
attenuation of the epigenetic regulators involved in Evi1-
mediated  transcriptional  silencing  potentially  restores 
the expression of several possible tumor suppressors and 
improves the extremely poor prognosis of leukemia with 
activated Evi1. 
Song et al. have recently reported that BMI1 induced 
epithelial–mesenchymal  transition  partially  through 
transcriptional  repression  of  PTEN  in  nasopharyngeal 
epithelial cells (NPECs) [106]. These results and those 
of  our  study  have  suggested  that  PcG  proteins  can 
target  PTEN/AKT/mTOR  signaling  under  specific 
circumstances. Our study proposes that one such condition 
in the hematopoietic system is high Evi1 activity because 
PcG  proteins  did  not  affect  PTEN transcription in 
hematopoietic cells with low Evi1 expression. Meanwhile, 
it is yet to be determined whether anchor proteins like Evi1 
are required in BMI1-mediated PTEN regulation in NPEC 
or other cells. Interestingly, a recent genome association 
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effect of rapamycin on leukemia stem cells, GVL, or normal graft should be investigated more extensively.Oncotarget 2011; 2:  575 - 586 581 www.impactjournals.com/oncotarget
study of nasopharyngeal carcinoma identified MDS1/Evi1 
on 3q26 as a susceptibility locus [107]. Given that Evi1 
has been suggested to be implicated in several carcinomas 
other  than  hematopoietic  malignancies  [107-111],  deep 
insight into the function of Evi1 with regard to epigenetic 
regulation and signaling pathways may contribute to the 
development of molecularly targeted therapies for solid 
tumors such as colon cancer, lung cancer, nasopharyngeal 
carcinoma, and ovarian cancer. Particularly, PI3K/AKT 
signaling  is  one  of  the  most  frequently  and  aberrantly 
regulated pathways in human cancer [54,112-114], and 
Evi1-mediated AKT activation has been demonstrated in 
colon cancer cells [109]. These reports have suggested 
that  the  Evi1-AKT  axis  is  involved  with  several  solid 
tumors. In addition, there is increasing evidence showing 
aberrantly  activated  PI3K/AKT/mTORC1  signaling 
in  cancer  stem  cells,  including  leukemia  as  mentioned 
above [115-119]. Current clinical trials and studies using 
murine models have shown that rapamycin and rapalogs 
are less toxic to normal hematopoiesis than they are to 
malignancies and possibly less toxic to HSC than to LSC. 
More investigation for this scientific basis will enable us 
to develop rapamycin-containing therapy targeting AKT/
mTORC1 activity in cancer stem cells. 
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